



**WZ811** 

Catalog No: tcsc1003

<u>a</u>	Available Sizes
Size: 5	āmg
Size: 1	L0mg
Size: 5	50mg
Size: 1	L00mg
	Specifications
<b>CAS N</b> 55778-	
Formu	
Pathw GPCR/0	<b>ray:</b> G Protein;Immunology/Inflammation
Targe	
Purity >98%	/ Grade:
<b>Solub</b> i	ility: : 10 mg/mL (34.44 mM; Need ultrasonic)
Obser	ved Molecular Weight:

## **Product Description**

290.36

WZ811 is a potent **CXCR4** antagonist, effectively inhibits TN14003 binding to **CXCR4**, with an  $EC_{50}$  of 0.3 nM.



IC50 & Target: EC50: 0.3 nM (CXCR4)[1]

In Vitro: WZ811 (Compound 32) is a potent CXCR4 antagonist, effectively inhibits TN14003 binding to CXCR4, with an EC $_{50}$  of 0.3 nM. WZ811 also suppresses CXCR4/stromal cell-derived factor-1 (SDF-1)-mediated modulation of cyclic adenosine monophophate (cAMP) levels (EC $_{50}$ , 1.2 nM) and SDF-1 induced Matrigel invasion (EC $_{50}$ , 5.2 nM)<sup>[1]</sup>. WZ811 (1, 5, 10, 20, 40  $\mu$ M) inhibits TF-1 and UT-7 cells proliferation in a dose dependent manner both after treatment for 24 h and 48 h. Moreover, WZ811 (5  $\mu$ M) induces cell apoptosis and enhances the sensitivity of cells to docetaxel. In addition, WZ811 inhibits aggressiveness markers and induces apoptosis in chronic lymphocytic leukemia cells<sup>[2]</sup>.

*In Vivo:* WZ811 (40 mg/kg, p.o.) blocks the lymphocytic leukemia cells growth on mouse xenograft models, and inhibits CXCR4/PI3K/AKT signaling pathway in mouse xenograft model of lymphocytic leukemia<sup>[2]</sup>.

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!